Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

Next Previous
Trial Profile

Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LCL 161 (Primary) ; Topotecan (Primary) ; Granulocyte colony-stimulating factors
  • Indications Carcinoma; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 17 Aug 2021 Status changed from active, no longer recruiting to discontinued.
  • 12 Aug 2020 Planned End Date changed from 27 Jul 2020 to 30 Jul 2021.
  • 12 Aug 2020 Planned primary completion date changed from 27 Jul 2020 to 30 Jul 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top